Lawrence Lamb, Ph.D., Incysus Therapeutics Scientific Co-Founder to Present at Allogenic Cell Therapies Summit 2019 (ACTS)
May 02, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incycus Therapeutics Appoints Melissa Beelen as Vice President, Clinical Operations
April 03, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces FDA Approval of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly-Diagnosed Glioblastoma
April 01, 2019 08:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, April 01, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2019
March 19, 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta T Cell Immunotherapy Pioneer, Lawrence Lamb, PhD, to Join Incysus Therapeutics as Chief Scientific Officer
January 03, 2019 14:30 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to Its Board of Directors
January 03, 2019 14:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings
November 28, 2018 16:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
November 15, 2018 07:00 ET
|
Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...
Incysus Therapeutics to Participate in Panel at the 2018 Life Sciences Summit
October 22, 2018 08:00 ET
|
Incysus Therapeutics, Inc.
Panel Title: “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies” NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company...